Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,670 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer.
Sugimoto A, Kaneda H, Yoshimoto N, Nagata K, Fujii T, Michimoto K, Ueno S, Kamimori T, Ishii Y, Sakagami M, Inokuchi H, Shibuya K, Mizutani M, Nagamine H, Nakahama K, Matsumoto Y, Tani Y, Sawa K, Kawaguchi T. Sugimoto A, et al. Among authors: kawaguchi t. Sci Rep. 2024 Aug 23;14(1):19596. doi: 10.1038/s41598-024-70214-y. Sci Rep. 2024. PMID: 39179598 Free PMC article.
A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905.
Kurata T, Hirashima T, Iwamoto Y, Kawaguchi T, Ikeda N, Tsuboi M, Sawa T, Ishiguro T, Aoki T, Kotani Y, Nakagawa K, Fukuoka M. Kurata T, et al. Among authors: kawaguchi t. Lung Cancer. 2012 Jul;77(1):110-5. doi: 10.1016/j.lungcan.2011.12.016. Epub 2012 Feb 3. Lung Cancer. 2012. PMID: 22306126 Clinical Trial.
[Discussion. Meeting on the diagnosis and treatment of lung cancer].
Hirata K, Takayama K, Kawaguchi T, Sawa K, Ohsaki Y. Hirata K, et al. Among authors: kawaguchi t. Nihon Naika Gakkai Zasshi. 2014 Jun 10;103(6):1360-74; quiz 1375-81. doi: 10.2169/naika.103.1360. Nihon Naika Gakkai Zasshi. 2014. PMID: 25151802 Japanese. No abstract available.
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
Yoshimura N, Kudoh S, Mitsuoka S, Yoshimoto N, Oka T, Nakai T, Suzumira T, Matusura K, Tochino Y, Asai K, Kimura T, Kawaguchi T, Hirata K. Yoshimura N, et al. Among authors: kawaguchi t. Lung Cancer. 2015 Oct;90(1):65-70. doi: 10.1016/j.lungcan.2015.06.002. Epub 2015 Jun 15. Lung Cancer. 2015. PMID: 26238424 Clinical Trial.
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N; West Japan Oncology Group. Shukuya T, et al. Among authors: kawaguchi t. Lancet Oncol. 2015 Dec;16(16):1630-8. doi: 10.1016/S1470-2045(15)00305-8. Epub 2015 Oct 28. Lancet Oncol. 2015. PMID: 26522337 Clinical Trial.
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Mitsuoka S, Kawaguchi T, Kubo A, Isa S, Asai K, Uji M, Watanabe T, Sawa K, Yoshimoto N, Oka T, Nakai T, Suzumura T, Tanaka H, Matsuura K, Kimura T, Yoshimura N, Kudoh S, Hirata K. Mitsuoka S, et al. Among authors: kawaguchi t. Expert Opin Pharmacother. 2016;17(2):193-203. doi: 10.1517/14656566.2016.1109635. Epub 2016 Jan 18. Expert Opin Pharmacother. 2016. PMID: 26781399 Review.
Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M, Tamiya A, Yasue T, Nakao K, Omachi N, Shiroyama T, Tani E, Hamaguchi M, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Hirashima T. Tamiya M, et al. Among authors: kawaguchi t. Anticancer Res. 2016 Jun;36(6):2939-44. Anticancer Res. 2016. PMID: 27272808
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
Tambo Y, Hosomi Y, Sakai H, Nogami N, Atagi S, Sasaki Y, Kato T, Takahashi T, Seto T, Maemondo M, Nokihara H, Koyama R, Nakagawa K, Kawaguchi T, Okamura Y, Nakamura O, Nishio M, Tamura T. Tambo Y, et al. Among authors: kawaguchi t. Invest New Drugs. 2017 Apr;35(2):217-226. doi: 10.1007/s10637-017-0435-2. Epub 2017 Jan 30. Invest New Drugs. 2017. PMID: 28138828 Clinical Trial.
2,670 results